Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study

被引：4

作者：

Omachi, Takemasa ^{[1
]}

Ohara, Makoto ^{[1
]}

Fujikawa, Tomoki ^{[1
]}

Kohata, Yo ^{[1
]}

Sugita, Hiroe ^{[1
]}

Irie, Shunichiro ^{[2
,3
]}

Terasaki, Michishige ^{[1
]}

Mori, Yusaku ^{[4
]}

Fukui, Tomoyasu ^{[1
]}

Yamagishi, Sho-ichi ^{[1
]}

机构：

[1] Showa Univ, Sch Med, Dept Med, Div Diabet Metab & Endocrinol, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428666, Japan

[2] Tokatsu Hosp, Dept Internal Med, Chiba, Japan

[3] Tokatsu Hosp, Huzoku Nagareyama Cent Pk Ekimae Clin, Dept Internal Med, Chiba, Japan

[4] Showa Univ, Sch Med, Div Diabet Metab & Endocrinol, Dept Med,Antiglycat Res Sect, Tokyo, Japan

来源：

DIABETES THERAPY | 2024年 / 15卷 / 01期

关键词：

Continuous glucose monitoring; Glucagon-like peptide-1 receptor agonists; Glucose variability; Oxidative stress; Type 2 diabetes mellitus; GLYCEMIC VARIABILITY; LIRAGLUTIDE; HYPERGLYCEMIA; RESPONSES; DISEASE;

D O I：

10.1007/s13300-023-01493-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionRecent trials have shown that glucagon-like peptide-1 receptor agonists considerably reduce atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Oxidative stress, a surrogate marker of cardiovascular risk, is associated with glucose variability. However, to the best of our knowledge, no studies have compared the effects of injectable semaglutide and dulaglutide therapies on oxidative stress and glucose variability assessed via continuous glucose monitoring (CGM). This study aimed to analyze and compare the effects of semaglutide and dulaglutide therapies on oxidative stress and glucose variability as assessed through CGM.MethodsThis is an open-label, multicenter, randomized, prospective, parallel-group comparison study. Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups. The coprimary endpoints were changes in the results of the diacron-reactive oxygen metabolites test, an oxidative stress marker, and CGM-evaluated glucose variability after 24 weeks. The secondary endpoint was changes in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores.ResultsSwitching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels. Conversely, continuous dulaglutide therapy was better than semaglutide therapy in terms of DTSQ scores for "Convenience" and "Recommend."ConclusionInjectable semaglutide therapy may be more effective than dulaglutide therapy in ameliorating oxidative stress and regulating glucose metabolism, including glucose variability, in patients with T2DM, while dulaglutide therapy may be more effective in terms of treatment satisfaction.Clinical Trial RegistrationUMIN-CRT ID: UMIN000042670 (registered 7 December 2020).

引用

页码：111 / 126

页数：16